Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Summit Therapeutics

Nasdaq:SMMT
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SMMT
Nasdaq
$164M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Summit Therapeutics plc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. The last earnings update was 102 days ago. More info.


Add to Portfolio Compare Print
  • Summit Therapeutics has significant price volatility in the past 3 months.
SMMT Share Price and Events
7 Day Returns
4.5%
NasdaqGM:SMMT
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
33.3%
NasdaqGM:SMMT
1.6%
US Biotechs
-9.1%
US Market
SMMT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Summit Therapeutics (SMMT) 4.5% 75.5% 57.4% 33.3% -81.6% -81.3%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • SMMT outperformed the Biotechs industry which returned 1.6% over the past year.
  • SMMT outperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
SMMT
Industry
5yr Volatility vs Market

SMMT Value

 Is Summit Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Summit Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $2.44.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Summit Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Summit Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:SMMT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-10-31) in GBP £-0.73
NasdaqGM:SMMT Share Price ** NasdaqGM (2020-03-27) in USD $2.44
NasdaqGM:SMMT Share Price converted to GBP reporting currency Exchange rate (USD/ GBP) 0.806 £1.97
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Summit Therapeutics.

NasdaqGM:SMMT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SMMT Share Price ÷ EPS (both in GBP)

= 1.97 ÷ -0.73

-2.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Summit Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Summit Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Summit Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:SMMT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.69x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
46.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Summit Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Summit Therapeutics's assets?
Raw Data
NasdaqGM:SMMT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-10-31) in GBP £0.84
NasdaqGM:SMMT Share Price * NasdaqGM (2020-03-27) in USD $2.44
NasdaqGM:SMMT Share Price converted to GBP reporting currency Exchange rate (USD/ GBP) 0.806 £1.97
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:SMMT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SMMT Share Price ÷ Book Value per Share (both in GBP)

= 1.97 ÷ 0.84

2.35x

* Primary Listing of Summit Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Summit Therapeutics is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Summit Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Summit Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SMMT Future Performance

 How is Summit Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
46.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Summit Therapeutics expected to grow at an attractive rate?
  • Summit Therapeutics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Summit Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Summit Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:SMMT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:SMMT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 46.8%
NasdaqGM:SMMT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 25.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:SMMT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:SMMT Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 60 27 1
2023-12-31 25 15 1
2022-12-31 3 -10 1
2021-12-31 3 -22 1
2020-12-31 18 -18 1
2020-03-28
2019-12-31 16 -19 1
NasdaqGM:SMMT Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-10-31 20 -18 -21
2019-07-31 20 -16 -22
2019-04-30 55 -18 9
2019-01-31 58 -27 8
2018-10-31 55 -28 1
2018-07-31 55 -34 9
2018-04-30 20 -14 -21
2018-01-31 14 -15 -20
2017-10-31 12 -15 -14
2017-07-31 9 23 -18
2017-04-30 4 11 -21
2017-01-31 2 12 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Summit Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Summit Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:SMMT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Summit Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SMMT Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.08 0.08 0.08 1.00
2023-12-31 0.05 0.05 0.05 1.00
2022-12-31 -0.03 -0.03 -0.03 1.00
2021-12-31 -0.07 -0.07 -0.07 1.00
2020-12-31 -0.05 -0.05 -0.05 1.00
2020-03-28
2019-12-31 -0.11 -0.11 -0.11 1.00
NasdaqGM:SMMT Past Financials Data
Date (Data in GBP Millions) EPS *
2019-10-31 -0.73
2019-07-31 -0.89
2019-04-30 0.44
2019-01-31 0.44
2018-10-31 0.09
2018-07-31 0.58
2018-04-30 -1.54
2018-01-31 -1.54
2017-10-31 -1.10
2017-07-31 -1.42
2017-04-30 -1.68
2017-01-31 -1.74

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Summit Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Summit Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Summit Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SMMT Past Performance

  How has Summit Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Summit Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Summit Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Summit Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Summit Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Summit Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Summit Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SMMT Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-10-31 20.12 -21.34 9.51 34.25
2019-07-31 19.56 -22.45 9.79 35.22
2019-04-30 55.50 9.34 10.92 35.86
2019-01-31 57.62 7.53 11.59 39.17
2018-10-31 54.70 1.37 14.41 39.54
2018-07-31 55.13 8.64 11.73 38.77
2018-04-30 19.61 -21.27 11.89 35.53
2018-01-31 14.17 -20.19 12.00 28.97
2017-10-31 11.51 -13.83 9.93 23.86
2017-07-31 8.78 -17.55 9.86 20.39
2017-04-30 4.05 -20.70 9.28 19.18
2017-01-31 2.38 -21.37 8.28 18.95
2016-10-31 0.87 -23.57 6.64 19.16
2016-07-31 0.52 -24.60 6.04 19.70
2016-04-30 0.93 -22.21 5.13 18.53
2016-01-31 1.28 -20.14 4.77 16.86
2015-10-31 1.60 -16.03 4.69 14.63
2015-07-31 1.84 -12.86 4.02 12.73
2015-04-30 1.92 -12.11 4.62 10.99
2015-01-31 1.89 -11.38 3.70 10.42
2014-10-31 2.07 -10.63 3.76 9.89
2014-07-31 2.48 -9.86 3.59 9.57
2014-04-30 2.23 -7.65 2.42 8.13
2014-01-31 1.84 -6.09 1.94 6.61
2013-10-31 -0.03 -4.81 1.79 5.51
2013-07-31 1.30 -4.13 1.82 3.85
2013-04-30 1.56 -4.18 1.79 3.74

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Summit Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Summit Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Summit Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Summit Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Summit Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SMMT Health

 How is Summit Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Summit Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Summit Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Summit Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Summit Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Summit Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Summit Therapeutics Company Filings, last reported 4 months ago.

NasdaqGM:SMMT Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-10-31 26.86 0.00 13.60
2019-07-31 33.71 0.00 20.87
2019-04-30 38.64 0.00 28.32
2019-01-31 42.54 0.00 26.86
2018-10-31 28.03 0.00 13.04
2018-07-31 33.05 0.00 17.13
2018-04-30 5.77 0.00 27.69
2018-01-31 -3.18 0.00 20.10
2017-10-31 16.10 0.00 31.81
2017-07-31 3.50 0.00 28.29
2017-04-30 -7.98 0.00 19.36
2017-01-31 -3.49 0.00 28.06
2016-10-31 1.09 0.00 34.63
2016-07-31 10.57 0.00 7.00
2016-04-30 16.33 0.00 9.99
2016-01-31 16.08 0.00 16.30
2015-10-31 25.91 0.00 22.19
2015-07-31 30.22 0.00 26.44
2015-04-30 33.87 0.00 29.41
2015-01-31 12.96 0.00 11.27
2014-10-31 17.66 0.00 15.01
2014-07-31 20.00 0.00 17.44
2014-04-30 4.76 0.00 2.03
2014-01-31 4.76 0.00 2.03
2013-10-31
2013-07-31 5.25 0.00 6.00
2013-04-30 5.25 0.00 6.00
  • Summit Therapeutics has no debt.
  • Summit Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Summit Therapeutics has less than a year of cash runway based on current free cash flow.
  • Summit Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.2% each year.
X
Financial health checks
We assess Summit Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Summit Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SMMT Dividends

 What is Summit Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Summit Therapeutics dividends.
If you bought $2,000 of Summit Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Summit Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Summit Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:SMMT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:SMMT Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Summit Therapeutics has not reported any payouts.
  • Unable to verify if Summit Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Summit Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Summit Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Summit Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Summit Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Summit Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SMMT Management

 What is the CEO of Summit Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Glyn Edwards
COMPENSATION £650,279
AGE 63
TENURE AS CEO 7.9 years
CEO Bio

Mr. Glyn O. Edwards, MBE, serves as Chief Executive Officer and Executive Director of Summit Therapeutics plc since April 4, 2012 and served as its Chairman since December 24, 2019 until February 26, 2020. Mr. Edwards has a wealth of expertise garnered from a thirty-year career in the life sciences industry, during which time he has held a number of senior executive and business development roles. He served as the Chief Executive Officer of Antisoma plc since March 1998 and served as its Executive Director since March 16, 1998 until February 28, 2011. Prior to joining Antisoma, he served as the Vice President of Business Development at Therapeutic Antibodies Inc. since January 1998. He has worked with Celltech PLC and 3M United Kingdom PLC. Mr. Edwards was the Founder of Oros Instruments Limited. From 1995 to 1998, he served as a Consultant of TAb through Elara Associates Limited. Mr. Edwards served as the Chairman of Executive Board and Member of Executive Board at Antisoma Research Limited. He serves as an Executive Director at Xanthus Pharmaceuticals, Inc. He serves as a Director of Elara Associates Limited, Cancer Therapeutics Limited. Mr. Edwards is a Member of Review Panel of Heptagon Fund. He holds a BS degree in Biochemistry from Bristol University and an MS degree in Economics from London Business School.

CEO Compensation
  • Glyn's compensation has increased whilst company is loss making.
  • Glyn's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Summit Therapeutics management team in years:

4.5
Average Tenure
60
Average Age
  • The tenure for the Summit Therapeutics management team is about average.
Management Team

Glyn Edwards

TITLE
CEO & Executive Director
COMPENSATION
£650K
AGE
63
TENURE
7.9 yrs

Bob Duggan

TITLE
Executive Chairman
AGE
75
TENURE
0.1 yrs

Kay Davies

TITLE
Co-Founder
AGE
69

Melissa Strange

TITLE
VP of Finance & Company Secretary
AGE
39
TENURE
1.3 yrs

Dave Powell

TITLE
Senior VP & Head of Research
AGE
50

Richard Vickers

TITLE
Chief Scientific Officer & Senior VP of Research and Development?
AGE
43

Michelle Avery

TITLE
Director of Investor Relations
TENURE
4.5 yrs

Richard Pye

TITLE
Senior Director of Corporate Affairs & Communications

Anna Triola

TITLE
Vice President of Marketing

Jonathon Tinsley

TITLE
Chief Scientific Officer of DMD
AGE
60
TENURE
6.4 yrs
Board of Directors

Glyn Edwards

TITLE
CEO & Executive Director
COMPENSATION
£650K
AGE
63
TENURE
7.9 yrs

Bob Duggan

TITLE
Executive Chairman
AGE
75
TENURE
0.1 yrs

Kay Davies

TITLE
Co-Founder
AGE
69

Marcel van den Heuvel

TITLE
Member of Scientific Advisory Board

Francesco Muntoni

TITLE
Member of Scientific Advisory Board

Roger Patient

TITLE
Member of Scientific Advisory Board

Edith Sim

TITLE
Member of Scientific Advisory board

Bob Sim

TITLE
Member of Scientific Advisory board

Derek Stemple

TITLE
Member of Scientific Advisory board

Jean-Paul Vincent

TITLE
Member of Scientific Advisory board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Summit Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Summit Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SMMT News

Simply Wall St News

SMMT Company Info

Description

Summit Therapeutics plc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-571, a preclinical stage candidate to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Details
Name: Summit Therapeutics plc
SMMT
Exchange: NasdaqGM
Founded: 2003
$164,045,840
67,231,902
Website: http://www.summitplc.com
Address: Summit Therapeutics plc
136a Eastern Avenue,
Milton Park,
Abingdon,
Oxfordshire, OX14 4SB,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SMMT SPONS ADS Nasdaq Global Market US USD 06. Mar 2015
Number of employees
Current staff
Staff numbers
61
Summit Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:56
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/19
Last earnings filing: 2019/12/17
Last earnings reported: 2019/10/31
Last annual earnings reported: 2019/01/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.